Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia


  • Cantex to receive $30M up front, $587.5M regulatory and commercial milestones and royalties starting at 10%. Chimerix to get exclusive WW rights to develop and commercialize Cantex’s CX-01 and has also issued $10M shares in its common stock to Cantex
  • The focus of the agreement is to accelerate and advance the development of CX-01 with the initiation of P-III trial for treating 1L AML patients in H2’20
  • CX-01 is a chemical candidate derived from unfractionated heparin with very low anticoagulant activity targeting protein pathways for AML and has also received the US FDA’s FT designation. CX-01 was recently evaluated in P-II trial with newly diagnosed AML demonstrated well tolerated results

Click here to­ read full press release/ article | Ref: Chimerix | Image: Behnace